FLUX
DYNAMIC MEASUREMENT
Perfused microfluidics hold living organoids in a controlled microenvironment while time-resolved metabolomics capture bioenergetic flux in real time — the dynamic readout static assays can't see.
Drug discovery platform for complex disease using physics-driven AI and microfluidic metabolomics.
FLUX measures living metabolism as it happens; FORCE turns those dynamics into predictive, physics-constrained models. Together they form a continuous measure → infer → design loop.
DYNAMIC MEASUREMENT
Perfused microfluidics hold living organoids in a controlled microenvironment while time-resolved metabolomics capture bioenergetic flux in real time — the dynamic readout static assays can't see.
PREDICTIVE INTELLIGENCE
Physics-constrained models turn measurement into a navigable map of cell-state space — resolving disease from health and predicting which interventions move metabolism where you want it.
Cellular state is governed by dynamic bioenergetic control architecture. Meteor is building tools to learn and reprogram that layer.
What we learn about bioenergetic control becomes the blueprint for intervention — a new class of de novo small molecule metabolic transducers, designed to guide cells back toward a healthy state.
Designed from first principles.
FORCE operates internally in a richer state-space representation — one that surfaces structure standard metabolomics misses. We translate that into decision support in the formats your teams already run on, with no new interpretive infrastructure to absorb.
A more powerful engine, familiar deliverables.
WHAT PARTNERS RECEIVE
Tyler Quarton came to metabolism from computational biology at NASA; Gabriel Trisca from building AI at Google. Together they lead a team decoding — and reprogramming — the control layer of disease.
WHY METEOR
We use physics-constrained models and dynamic measurements to reveal bioenergetic control mechanisms with predictive fidelity.
Our integrated microfluidics + metabolomics platform is built for speed, scale, and reproducibility across disease models.
We collaborate closely with pharma, biotech, and academic partners to co-develop programs from biology to candidate insight.